Detalles de la búsqueda
1.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Ann Neurol
; 91(6): 782-795, 2022 06.
Artículo
Inglés
| MEDLINE | ID: mdl-35289960
2.
Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
J Neurol Neurosurg Psychiatry
; 2023 Dec 06.
Artículo
Inglés
| MEDLINE | ID: mdl-38071574
3.
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Mult Scler
; 24(14): 1862-1870, 2018 12.
Artículo
Inglés
| MEDLINE | ID: mdl-30415593
4.
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Ann Rheum Dis
; 76(6): 1078-1085, 2017 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-28007755
5.
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
N Engl J Med
; 366(1): 20-33, 2012 Jan 05.
Artículo
Inglés
| MEDLINE | ID: mdl-22077816
6.
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Ann Clin Transl Neurol
; 2024 May 07.
Artículo
Inglés
| MEDLINE | ID: mdl-38713096
7.
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Ann Clin Transl Neurol
; 10(4): 579-588, 2023 04.
Artículo
Inglés
| MEDLINE | ID: mdl-36811392
8.
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.
Mult Scler Relat Disord
; 76: 104794, 2023 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-37356256
9.
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Eur J Clin Pharmacol
; 68(3): 291-300, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21969227
10.
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
Mult Scler Relat Disord
; 68: 104143, 2022 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-36031693
11.
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Ann Clin Transl Neurol
; 9(10): 1643-1659, 2022 10.
Artículo
Inglés
| MEDLINE | ID: mdl-36165097
12.
Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.
Mult Scler Relat Disord
; 52: 103010, 2021 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-34147885
13.
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
Arthritis Res Ther
; 23(1): 8, 2021 01 06.
Artículo
Inglés
| MEDLINE | ID: mdl-33407817
14.
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Lancet
; 373(9667): 919-28, 2009 Mar 14.
Artículo
Inglés
| MEDLINE | ID: mdl-19286091
15.
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis.
Rheumatol Ther
; 7(1): 165-171, 2020 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-31907758
16.
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
J Rheumatol
; 47(3): 325-332, 2020 03.
Artículo
Inglés
| MEDLINE | ID: mdl-31154414
17.
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability.
Mult Scler J Exp Transl Clin
; 6(1): 2055217320911939, 2020.
Artículo
Inglés
| MEDLINE | ID: mdl-32206332
18.
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Mult Scler Relat Disord
; 46: 102454, 2020 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-33045496
19.
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.
Rheumatol Ther
; 6(1): 77-88, 2019 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-30707391
20.
Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.
Arthritis Care Res (Hoboken)
; 2018 Oct 08.
Artículo
Inglés
| MEDLINE | ID: mdl-30295434